Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Decitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 5/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decitabine SCHEMBL117721 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL661233 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL4006 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL9999636 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL172264 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL10030513 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL18402620 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20651628 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20769771 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL12800474 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023078807-A1 | A CLASS IIA HDAC INHIBITOR AND DECITABINE TO TREAT MYOPATHY | UNIVERSITÄT BASEL (CH) | 2023-05-11 | — | — | WO | claimed |
| EP-4038187-A1 | OLIGONUCLEOTIDES WITH NUCLEOSIDE ANALOGS | Sirnaomics, Inc. (US) | 2022-08-10 | — | — | EP | claimed |
| CN-122070932-A | Application of combination of decitabine and anti-HER 2 antibody in preparation of medicines for treating tumors | 上海交通大学 | 2026-05-22 | — | — | CN | disclosed |
| WO-2026101931-A1 | METHODS OF TREATING MYELODYSPLASTIC SYNDROME | GERON CORPORATION (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260115223-A1 | METHODS OF TREATING MYELODYSPLASTIC SYNDROME | GERON CORP (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3658156-B1 | TELOMERASE INHIBITOR FOR USE IN TREATING A MYELODYSPLASTIC SYNDROME | GERON CORP (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2026044294-A1 | COMPOSITIONS COMPRISING AN ANTI-MIR-126 NUCLEIC ACID AND BCL-2 HOMOLOGY 3 (BH3) MIMETIC AND METHODS OF USE | CITY OF HOPE (US) | 2026-02-26 | — | — | WO | disclosed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| US-20250319183-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | AVIGAN DAVID (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4630818-A1 | METHODS OF TREATING AML BY IDENTIFYING AND TARGETING A MYELOID/LYMPHOID LEUKEMIA STEM CELL | The Regents of the University of Colorado, a body corporate (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC (CA) | 2009-09-10 | — | — | US | disclosed |
| US-20080293651-A1 | CYTOSINE NUCLEOSIDE ANALOGS AND ISOFLAVONES AND USES THEREOF | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2008-11-27 | — | — | US | disclosed |
| EP-1978930-A2 | SUTURES AND ANTI-SCARRING AGENTS | Angiotech Pharmaceuticals, Inc. (CA) | 2008-10-15 | — | — | EP | disclosed |
| US-20070207973-A1 | 1,3,5-Triazines for Treatment of Viral Diseases | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2007089878-A2 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2007-08-09 | — | — | WO | disclosed |
| US-20070142310-A1 | 1,3,5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| WO-2003045359-A2 | COMBINATION OF CIMETIDINE AND CYSTEINE DERIVATIVES FOR TREATING CANCER | ASTION ONCOLOGY APS (DK) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | DNMT1 1320/4885ADRB1 4277/4885LMNA 2558/4885 |
| US-20260115223-A1 | METHODS OF TREATING MYELODYSPLASTIC SYNDROME | TERT, POT1, TERF2 | DNMT1 33/4885ADRB1 4514/4885LMNA 308/4885 |
| US-20070207973-A1 | 1,3,5-Triazines for Treatment of Viral Diseases | HAVCR2, EIF2AK2, IKZF3 | DNMT1 1794/4885ADRB1 2787/4885LMNA 3236/4885 |
| US-20070142310-A1 | 1,3,5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | HAVCR2, EIF2AK2, IKZF3 | DNMT1 1794/4885ADRB1 2787/4885LMNA 3236/4885 |
| US-20250319183-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MCL1, BCL2, BCL3 | DNMT1 1530/4885ADRB1 4708/4885LMNA 1656/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | DNMT1 1457/4885ADRB1 746/4885LMNA 287/4885 |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | COL1A1, COL2A1, COL14A1 | DNMT1 2815/4885ADRB1 3780/4885LMNA 844/4885 |
| US-20080293651-A1 | CYTOSINE NUCLEOSIDE ANALOGS AND ISOFLAVONES AND USES THEREOF | TYMP, NUDT1, PCNA | DNMT1 53/4885ADRB1 4517/4885LMNA 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.